Search
Aurinia Pharmaceuticals Inc
AUPHAdd to Watchlist
16.400USD
-0.270-1.62%
Close 09-23 16:00（ET）
2.11BMarket Cap
7.36P/E TTM
About Aurinia Pharmaceuticals Inc Company
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Aurinia Pharmaceuticals Inc Profile
Ticker SymbolAUPH
Company nameAurinia Pharmaceuticals Inc
IPO dateJul 16, 2001
CEOGreenleaf (Peter S)
Number of employees130
Security typeOrdinary Share
Fiscal year-endJul 16
Address#140, 14315 - 118 Avenue
CityEDMONTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT5L 4S6
Phone12507442487
Websitehttps://www.auriniapharma.com
Ticker SymbolAUPH
IPO dateJul 16, 2001
CEOGreenleaf (Peter S)
Company Executives of Aurinia Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+31.87%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
356.27K
-3.35%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
356.27K
-3.35%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
356.27K
-3.35%
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
116.14K
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
116.14K
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
116.14K
--
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
28.53K
+59.79%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-21.87%
Mr. Jeffrey A. Bailey
Mr. Jeffrey A. Bailey
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+31.87%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
356.27K
-3.35%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
356.27K
-3.35%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
356.27K
-3.35%
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
116.14K
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
116.14K
--
FAQs
Who are the top five shareholders of Aurinia Pharmaceuticals Inc?
The top five shareholders of Aurinia Pharmaceuticals Inc are: Mr. Peter S. Greenleaf
How many institutions hold shares of Aurinia Pharmaceuticals Inc (AUPH)?
As of 2026Q1, 483 institutions hold shares of Aurinia Pharmaceuticals Inc, with a combined market value of approximately 74.86M, accounting for 58.21% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -419172.00.